Slingshot members are tracking this event:
Celgene (CELG) Presents Phase 2 Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis at AGG Plenary Session
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Oct 19, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2, Ozanimod, Severe Ulcerative Colitis, Touchstone Trial